Speaker
Zhibo Liu
(Peking University)
Summary
We developed a novel ¹⁸⁸Re-labeled PSMA inhibitor using a proprietary N₃S chelator, demonstrating enhanced stability and superior tumor targeting. The optimized agent achieved 100% complete tumor regression with no recurrence in mice, coupled with rapid renal clearance to minimize toxicity. As a generator-produced isotope, ¹⁸⁸Re presents a scalable and cost-effective theranostic platform for advanced cancer treatment, particularly in resource-limited settings
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
Authors
Mengxin Xu
Zhibo Liu
(Peking University)
